Page 2 - Read Online
P. 2
Topic: Systemic Treatment for
Hepatocellular Carcinoma
The systemic treatment of advanced hepatocellular
carcinoma has rapidly evolved in the last years. Until
the demonstration of the survival benefit of sorafenib
in 2007, no effective treatments were available. The
positive results with sorafenib represented a major
breakthrough and triggered interest in the evaluation of
new agents. After multiple failures, recent agents have
proven benefit, significantly extending the survival
Flair José Carrilho, MD, of advanced hepatocellular carcinoma. This hopeful
PhD scenario has been crowned by the recently published
results of the IMBRAVE-150 trial. This trial proved
EASL International Recognition Award superiority of atezolizumab plus bevacizumab over
Recipient 2019; sorafenib. Currently, several ongoing trials are evaluating
Head of the Division of Clinical the activity of dual immunotherapy combinations
Gastroenterology and Hepatology, Hospital or combinations of tyrosine kinase inhibitors plus
das Clínicas HCFMUSP, Department of
Gastroenterology, University of São Paulo immunotherapy. Some of these results are planned to be
School of Medicine, Sao Paulo, Brazil. announced in the following years. Within this context,
it is possible to state that advanced HCC will move
from a rapidly lethal malignancy to a chronic condition.
This will require critical insight and deep knowledge
of the available data. We invite you to contribute to the
upcoming Special Issue about “Systemic Treatment for
Hepatocellular Carcinoma” and hope you will be able to
join us in this journey.
